AgingResearch.NewsJoin free

AbelZeta

CompanyUnited States

AbelZeta develops one asset, in phase 1 (C-CAR168 in autoimmune). Mostly cell therapy acting on TNFRSF17 and MS4A1; based in the United States.

1
Asset
Furthest stage
Phase 1
1
Trial
2
Signals

Pipeline

1

  • C-CAR168

    Autologous CAR T cells target CD20- and BCMA-expressing cells to deplete pathogenic B cells and plasma cells.

    Phase 1, Cell therapy, TNFRSF17, MS4A1, autoimmune, MS

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials1
  • Signals2
  • Similar companies6

Intelligence